Skip to content
Search

Latest Stories

Pharmacy bodies voice concerns over LFT shortage as demand continues to surge

Following intermittent shortages during the holiday period and amid continued high level of demand for lateral flow tests (LFT) in pharmacies, the industry has voiced concerns over supplies.

Royal Pharmaceutical Society in England chair Thorrun Govind recently gave numerous media interviews over the issue, supporting pharmacists and reassuring the public.


She said it is ‘frustrating’ for pharmacy teams who are unable to access enough test kits to meet the growing demand and highlighted that placing all supplies with a single distributor as a key issue.

Many in the sector have raised questions about the government’s strategy for LFT distribution after it emerged that the sole distributor to pharmacies closed for four days shortly after receiving 2.5 million tests.

Alliance Healthcare, from whom pharmacies receive LFTs, reportedly took delivery of the tests on Christmas Eve and then shut.

THORRUN GOVIND Thorrun Govind, chair of RPS in England

Talking to BBC this week, Govind said: “It's hard to understand why there was only one sole distributor of these lateral flow tests in England, and it's very frustrating for our pharmacy teams who faced the public's reaction to not being able to access lateral flow tests.”

She said that going forward the government needs to think whether it is appropriate to have a sole distributor of LFTs to pharmacies.

She added: “We also need to consider the impact of the lateral flow test been provided with a code which the public presume results in a lateral flow test being provided at that pharmacy like a click and collect order.”

Emphasizing on the surge in demand for tests, Govind said: “Sometimes they're not lasting longer than an hour. We're getting a container which is about 56 boxes of lateral flow tests and they really are going straight out the door as soon as they're getting them.”

She further highlighted that healthcare teams, pharmacists, and their support staff have been working incredibly hard through the pandemic.

RPS has called for improving the supply of LFT kits and urged the public to be patient during this period.

The National Pharmacy Association (NPA) has also urged the government to decide on prioritizing supplies as demand for LFTs continues to rise.

NPA director of corporate affairs, Gareth Jones, said: “It’s easy for people to imagine that the supply problems will go away because Christmas and New Year are over. However, there will be new demand driven by people returning to work and school in the weeks ahead.

“If the government can’t guarantee enough supply to meet the demand created by their policies then there needs to be a candid conversation with the public about prioritizing essential workers including health care staff.”

He added that these decisions are vital to avoid frustration among the public “and to prevent blame falling unfairly on pharmacy teams and the medicines supply chain.”

Since the start of the Pharmacy Collect scheme, pharmacies have distributed nearly 300 million LFT kits.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less